22 research outputs found
Peripherally acting alpha-adrenoceptor antagonist MK-467 with intramuscular medetomidine and butorphanol in dogs : A prospective, randomised, clinical trial
Peer reviewe
Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a glibenclamide-induced canine hypoglycaemia model
The commonly used sedative α2-adrenoceptor agonist
dexmedetomidine has adverse cardiovascular effects in dogs that can be
prevented by concomitant administration of the peripherally acting α2-adrenoceptor
antagonist MK-467. An ancillary effect of dexmedetomidine is to
decrease insulin release from the pancreas, whereas MK-467 stimulates
insulin release. This study assessed the effects of co-administered
dexmedetomidine and MK-467 in a canine glibenclamide-induced
hypoglycaemia model. In a randomised, cross-over experiment, eight
beagle dogs received five intravenous treatments, comprising two
administrations of saline, with dexmedetomidine or dexmedetomidine and
MK-467, and three administrations of glibenclamide, with saline,
dexmedetomidine or dexmedetomidine and MK-467. Plasma concentrations of
glucose, lactate, insulin, glucagon and the test drugs were monitored.
Administration of glibenclamide significantly increased insulin
secretion and decreased blood glucose concentrations. Dexmedetomidine
counteracted glibenclamide-evoked hypoglycaemia. This was opposed by the
α2-adrenoceptor antagonist MK-467, but the
glibenclamide-evoked hypoglycaemia was not potentiated by
co-administration of dexmedetomidine and MK-467. None of the dogs
developed uncontrolled hypoglycaemia. Thus, the combination of
dexmedetomidine and MK-467 appeared to be safe in this canine
hypoglycaemia model. Nevertheless, when MK-467 is used to alleviate the
undesired cardiovascular effects of α2-adrenoceptor agonists
in dogs, it should be used with caution in animals at risk for
hypoglycaemia because of its insulin-releasing and hypoglycaemic
effects.</p
Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer
Peer reviewe
Genetic architecture of human plasma lipidome and its link to cardiovascular disease
Understanding genetic architecture of plasma lipidome could provide better insights into lipid metabolism and its link to cardiovascular diseases (CVDs). Here, we perform genome-wide association analyses of 141 lipid species (n = 2,181 individuals), followed by phenome-wide scans with 25 CVD related phenotypes (n = 511,700 individuals). We identify 35 lipid-species-associated loci (P <5 x10(-8)), 10 of which associate with CVD risk including five new loci-COL5A1, GLTPD2, SPTLC3, MBOAT7 and GALNT16 (false discovery rate<0.05). We identify loci for lipid species that are shown to predict CVD e.g., SPTLC3 for CER(d18:1/24:1). We show that lipoprotein lipase (LPL) may more efficiently hydrolyze medium length triacylglycerides (TAGs) than others. Polyunsaturated lipids have highest heritability and genetic correlations, suggesting considerable genetic regulation at fatty acids levels. We find low genetic correlations between traditional lipids and lipid species. Our results show that lipidomic profiles capture information beyond traditional lipids and identify genetic variants modifying lipid levels and risk of CVD
Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a glibenclamide-induced canine hypoglycaemia model
The commonly used sedative alpha(2)-adrenoceptor agonist dexmedetomidine has adverse cardiovascular effects in dogs that can be prevented by concomitant administration of the peripherally acting alpha(2)-adrenoceptor antagonist MK-467. An ancillary effect of dexmedetomidine is to decrease insulin release from the pancreas, whereas MK-467 stimulates insulin release. This study assessed the effects of co-administered dexmedetomidine and MK-467 in a canine glibenclamide-induced hypoglycaemia model. In a randomised, cross-over experiment, eight beagle dogs received five intravenous treatments, comprising two administrations of saline, with dexmedetomidine or dexmedetomidine and MK-467, and three administrations of glibenclamide, with saline, dexmedetomidine or dexmedetomidine and MK-467. Plasma concentrations of glucose, lactate, insulin, glucagon and the test drugs were monitored. Administration of glibenclamide significantly increased insulin secretion and decreased blood glucose concentrations. Dexmedetomidine counteracted glibenclamide-evoked hypoglycaemia. This was opposed by the alpha(2)-adrenoceptor antagonist MK-467, but the glibenclamide-evoked hypoglycaemia was not potentiated by co-administration of dexmedetomidine and MK-467. None of the dogs developed uncontrolled hypoglycaemia. Thus, the combination of dexmedetomidine and MK-467 appeared to be safe in this canine hypoglycaemia model. Nevertheless, when MK-467 is used to alleviate the undesired cardiovascular effects of alpha(2)-adrenoceptor agonists in dogs, it should be used with caution in animals at risk for hypoglycaemia because of its insulin-releasing and hypoglycaemic effects. (C) 2018 The Author(s). Published by Elsevier Ltd.Peer reviewe